Inhibition of CREBBP function with small molecule inhibitors could phenocopy this synthetic lethal effect, sensitizing diverse subtypes of B-ALL to BCL2 inhibitors in-vitro and producing a significant survival advantage in-vivo, thus providing a potentially efficacious drug combination across a wider number of B-ALL genotypes. This evidence concerns the gene BCL2 and precursor B-cell acute lymphoblastic leukemia.